130 related articles for article (PubMed ID: 27244269)
21. Analysis of antibody response to HPV 16 and HPV 18 antigens in Tunisian patients.
Achour M; Kahla S; Zeghal D; Kochbati L; Mongi M; Zouari F; Oueslati R
Viral Immunol; 2009 Feb; 22(1):7-16. PubMed ID: 19210223
[TBL] [Abstract][Full Text] [Related]
22. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
Stanley M; Lowy DR; Frazer I
Vaccine; 2006 Aug; 24 Suppl 3():S3/106-13. PubMed ID: 16949996
[TBL] [Abstract][Full Text] [Related]
23. Prophylactic HPV vaccines: reducing the burden of HPV-related diseases.
Villa LL
Vaccine; 2006 Mar; 24 Suppl 1():S23-8. PubMed ID: 16194583
[TBL] [Abstract][Full Text] [Related]
24. New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention.
Gersch ED; Gissmann L; Garcea RL
Antivir Ther; 2012; 17(3):425-34. PubMed ID: 22293302
[TBL] [Abstract][Full Text] [Related]
25. In silico DNA vaccine designing against human papillomavirus (HPV) causing cervical cancer.
Gupta SK; Singh A; Srivastava M; Gupta SK; Akhoon BA
Vaccine; 2009 Dec; 28(1):120-31. PubMed ID: 19799841
[TBL] [Abstract][Full Text] [Related]
26. Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1.
Baud D; Ponci F; Bobst M; De Grandi P; Nardelli-Haefliger D
J Virol; 2004 Dec; 78(23):12901-9. PubMed ID: 15542642
[TBL] [Abstract][Full Text] [Related]
27. [Production of human papillomavirus type 16 virus-like particles and its immunogenicity].
Wei MX; Li SW; Huang B; Shen WT; Su YZ; Zhang CH; Gu Y; Du HL; Zhang J; Xia NS
Bing Du Xue Bao; 2009 Jul; 25(4):245-50. PubMed ID: 19769155
[TBL] [Abstract][Full Text] [Related]
28. Human papillomavirus 16 L1-E7 chimeric virus like particles show prophylactic and therapeutic efficacy in murine model of cervical cancer.
Sharma C; Dey B; Wahiduzzaman M; Singh N
Vaccine; 2012 Aug; 30(36):5417-24. PubMed ID: 22717329
[TBL] [Abstract][Full Text] [Related]
29. Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines.
Ahmed AI; Bissett SL; Beddows S
Infect Genet Evol; 2013 Aug; 18():151-9. PubMed ID: 23722024
[TBL] [Abstract][Full Text] [Related]
30. Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity.
Li Z; Song S; He M; Wang D; Shi J; Liu X; Li Y; Chi X; Wei S; Yang Y; Wang Z; Li J; Qian H; Yu H; Zheng Q; Yan X; Zhao Q; Zhang J; Gu Y; Li S; Xia N
Nat Commun; 2018 Dec; 9(1):5360. PubMed ID: 30560935
[TBL] [Abstract][Full Text] [Related]
31. A three component mix of thioredoxin-L2 antigens elicits broadly neutralizing responses against oncogenic human papillomaviruses.
Seitz H; Canali E; Ribeiro-Müller L; Pàlfi A; Bolchi A; Tommasino M; Ottonello S; Müller M
Vaccine; 2014 May; 32(22):2610-7. PubMed ID: 24662712
[TBL] [Abstract][Full Text] [Related]
32. Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection.
Karanam B; Jagu S; Huh WK; Roden RB
Immunol Cell Biol; 2009; 87(4):287-99. PubMed ID: 19421199
[TBL] [Abstract][Full Text] [Related]
33. [Expression of the human papillomavirus type 16L/E7 fusion protein in E. coli and observation of its immunogenicity in mice].
Tian HW; Ye ZM; Lu ZH; Jao R; Bian T; Zhao L; Ruan L
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Jun; 20(2):33-7. PubMed ID: 16816859
[TBL] [Abstract][Full Text] [Related]
34. [Polymorphisms of human papillomavirus type 81 L1 gene in patients with cervical lesions in Guangdong].
Zeng L; Yu SY; Hu ZH; Zhang J
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Dec; 28(12):2210-2. PubMed ID: 19114360
[TBL] [Abstract][Full Text] [Related]
35. Expression of HPV-11 L1 protein in transgenic Arabidopsis thaliana and Nicotiana tabacum.
Kohl TO; Hitzeroth II; Christensen ND; Rybicki EP
BMC Biotechnol; 2007 Sep; 7():56. PubMed ID: 17850660
[TBL] [Abstract][Full Text] [Related]
36. Papillomavirus-like particle based vaccines: cervical cancer and beyond.
Schiller JT; Lowy DR
Expert Opin Biol Ther; 2001 Jul; 1(4):571-81. PubMed ID: 11727495
[TBL] [Abstract][Full Text] [Related]
37. HPV vaccines to prevent cervical cancer and genital warts: an update.
Dochez C; Bogers JJ; Verhelst R; Rees H
Vaccine; 2014 Mar; 32(14):1595-601. PubMed ID: 24606637
[TBL] [Abstract][Full Text] [Related]
38. [Expression, purification and immunogenicity of human papillomavirus type 11 virus-like particles from Escherichia coli].
Yan C; Li S; Wang J; Wei M; Huang B; Zhuang Y; Li Z; Pan H; Zhang J; Xia N
Wei Sheng Wu Xue Bao; 2009 Nov; 49(11):1527-33. PubMed ID: 20112683
[TBL] [Abstract][Full Text] [Related]
39. Worldwide genetic variations in high-risk human papillomaviruses capsid L1 gene and their impact on vaccine efficiency.
Oumeslakht L; Ababou M; Badaoui B; Qmichou Z
Gene; 2021 May; 782():145533. PubMed ID: 33636291
[TBL] [Abstract][Full Text] [Related]
40. An effective DNA priming-protein boosting approach for the cervical cancer vaccination.
Kianmehr Z; Ardestani SK; Soleimanjahi H; Farahmand B; Abdoli A; Khatami M; Akbari K; Fotouhi F
Pathog Dis; 2015 Mar; 73(2):1-8. PubMed ID: 25722486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
